Developing T-cell therapies for lymphoma without receptor engineering.

ABSTRACT: T-cell therapy has emerged from the bench for the treatment of patients with lymphoma. Responses to T-cell therapeutics are regulated by multiple factors, including the patient's immune system status and disease stage. Outside of engineering of chimeric antigen receptors and artificial T-cell receptors, T-cell therapy can be mediated by ex vivo expansion of antigen-specific T cells targeting viral and/or nonviral tumor-associated antigens. These approaches are contributing to enhanced clinical responses and overall survival. In this review, we summarize the available T-cell therapeutics beyond receptor engineering for the treatment of patients with lymphoma.

SUBMITTER: Grant M 

PROVIDER: S-EPMC5728635 | biostudies-literature | 2017 Dec

REPOSITORIES: biostudies-literature